Technology
Health
Pharmaceutical

Mustang Bio

$3.17
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.13 (-4.00%) Today
+$0.05 (1.60%) As of 7:00 PM EDT after-hours

Why Robinhood?

You can buy or sell Mustang Bio and other stocks, options, ETFs, and crypto commission-free!

About MBIO

Mustang Bio, Inc. Common Stock, also called Mustang Bio, is a clinical-stage biopharmaceutical company that focuses on the development and commercialization of a broad range of proprietary chimeric antigen receptor engineered T cell (CAR T) immunotherapies and gene therapies. Read More It develops CAR T and CRISPR/Cas9-enhanced CAR T therapies across multiple cancers, as well as lentiviral gene therapy for XSCID. The firm's products include MB-101 IL13Ra2-specific CAR, MB-102 CD123 CAR, MB-103 HER2 CAR, MB-104 CS1 CAR, MB-105 PSCA CAR, MB-106 CD20 CAR, MB-107 XSCID Gene Therapy and Oncolytic Virus (C134). The company was founded on March 13, 2015 and is headquartered in New York, NY.

Employees
38
Headquarters
New York, New York
Founded
2015
Market Cap
92.82M
Price-Earnings Ratio
Dividend Yield
Average Volume
105.45K
High Today
$3.24
Low Today
$3.07
Open Price
$3.24
Volume
107.30K
52 Week High
$10.20
52 Week Low
$2.18

Collections

Technology
Health
Pharmaceutical
Medical
Biopharmaceutical
Gene Therapies
Therapy
2017 IPO

MBIO Earnings

Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
Actual
Expected Aug 12, Pre-Market
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.